Profile data is unavailable for this security.
About the company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
- Revenue in USD (TTM)139.74m
- Net income in USD-79.99m
- Incorporated2017
- Employees511.00
- LocationBeam Therapeutics Inc238 Main StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 327-8775
- Fax+1 (302) 655-5049
- Websitehttps://beamtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc | 3.08m | -126.35m | 2.37bn | 78.00 | -- | 4.33 | -- | 768.79 | -3.48 | -3.48 | 0.085 | 12.75 | 0.0066 | -- | 0.8013 | 39,461.54 | -27.12 | -37.13 | -28.32 | -39.78 | -- | -- | -4,104.78 | -3,874.39 | -- | -- | 0.00 | -- | 120.63 | -- | -95.08 | -- | -49.06 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.41bn | 118.00 | -- | 7.60 | -- | 249.18 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.47bn | 619.00 | -- | 11.26 | -- | 8.91 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | -- | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.52bn | 240.00 | -- | 3.22 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Disc Medicine Inc | 0.00 | -212.18m | 2.54bn | 155.00 | -- | 3.41 | -- | -- | -5.98 | -5.98 | 0.00 | 19.53 | 0.00 | -- | -- | 0.00 | -32.55 | -30.94 | -34.12 | -32.93 | -- | -- | -- | -- | -- | -- | 0.0379 | -- | -- | -- | -94.03 | -- | -- | -- |
| Arcus Biosciences Inc | 247.00m | -353.00m | 2.55bn | 601.00 | -- | 4.04 | -- | 10.34 | -3.30 | -3.30 | 2.30 | 5.04 | 0.2158 | -- | 12.05 | 410,981.70 | -30.84 | -18.85 | -38.54 | -22.29 | -- | -- | -142.92 | -103.61 | -- | -- | 0.1356 | -- | -4.26 | 26.08 | -24.73 | -- | -8.12 | -- |
| Wave Life Sciences Ltd | 42.73m | -204.38m | 2.62bn | 317.00 | -- | 5.04 | -- | 61.38 | -1.21 | -1.21 | 0.2534 | 2.80 | 0.0863 | -- | 31.67 | 134,785.50 | -41.26 | -44.67 | -52.09 | -71.58 | -- | -- | -478.33 | -208.12 | -- | -- | 0.00 | -- | -60.55 | 16.31 | -110.68 | -- | -11.71 | -- |
| Travere Therapeutics Inc | 490.73m | -50.26m | 2.75bn | 497.00 | -- | 23.59 | 262.15 | 5.60 | -0.603 | -0.3293 | 5.30 | 1.26 | 0.8184 | 1.71 | 9.15 | 987,382.30 | -8.38 | -37.69 | -11.99 | -48.59 | 97.89 | 96.60 | -10.24 | -116.71 | 2.70 | -- | 0.7308 | -- | 110.45 | 19.87 | 84.32 | -- | 18.81 | -- |
| Ideaya Biosciences Inc | 218.71m | -113.70m | 2.83bn | 145.00 | -- | 2.76 | -- | 12.93 | -1.30 | -1.30 | 2.46 | 11.65 | 0.1959 | -- | 73.20 | 1,508,345.00 | -10.18 | -18.78 | -10.68 | -20.00 | -- | -- | -51.99 | -185.86 | -- | -- | 0.00 | -- | 3,024.43 | 62.11 | 58.58 | -- | 36.87 | -- |
| Beam Therapeutics Inc | 139.74m | -79.99m | 2.90bn | 511.00 | -- | 2.34 | -- | 20.74 | -0.9703 | -0.9703 | 1.41 | 12.17 | 0.1081 | -- | -- | 273,469.70 | -6.19 | -19.28 | -6.94 | -22.57 | -- | -- | -57.24 | -176.36 | -- | -- | 0.00 | -- | 120.01 | 466.27 | 78.77 | -- | -1.79 | -- |
| Veracyte Inc | 517.15m | 66.35m | 2.91bn | 755.00 | 44.91 | 2.22 | 33.13 | 5.62 | 0.8147 | 0.8147 | 6.45 | 16.50 | 0.3822 | 7.31 | 11.34 | 684,960.30 | 4.90 | -1.69 | 5.17 | -1.78 | 70.10 | 67.87 | 12.83 | -5.22 | 7.81 | -- | 0.00 | -- | 16.01 | 34.50 | 174.89 | -- | 27.81 | -- |
| Vera Therapeutics Inc | 0.00 | -299.62m | 2.91bn | 249.00 | -- | 4.81 | -- | -- | -4.66 | -4.66 | 0.00 | 8.48 | 0.00 | -- | -- | 0.00 | -43.10 | -46.45 | -45.69 | -50.25 | -- | -- | -- | -- | -- | -- | 0.1102 | -- | -- | -- | -96.92 | -- | 44.79 | -- |
| Viridian Therapeutics Inc | 70.85m | -342.60m | 3.00bn | 252.00 | -- | 5.07 | -- | 42.38 | -4.00 | -4.00 | 0.8355 | 7.09 | 0.0863 | -- | -- | 281,146.80 | -41.73 | -44.39 | -44.98 | -47.63 | -- | -- | -483.57 | -1,390.51 | -- | -- | 0.1044 | -- | 23,359.93 | 132.18 | -26.91 | -- | 63.78 | -- |
| Edgewise Therapeutics Inc | 0.00 | -157.24m | 3.27bn | 136.00 | -- | 5.76 | -- | -- | -1.58 | -1.58 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -28.73 | -26.21 | -29.83 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
| Denali Therapeutics Inc | 0.00 | -512.54m | 3.36bn | 503.00 | -- | 3.26 | -- | -- | -2.97 | -2.97 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -40.69 | -25.08 | -44.21 | -29.47 | -- | -- | -- | -348.01 | -- | -- | 0.0055 | -- | -- | -- | -21.23 | -- | 25.15 | -- |
| Spyre Therapeutics Inc | 0.00 | -155.20m | 3.38bn | 102.00 | -- | 6.01 | -- | -- | -2.37 | -2.37 | 0.00 | 9.15 | 0.00 | -- | -- | 0.00 | -22.39 | -53.19 | -24.37 | -59.03 | -- | -- | -- | -3,879.14 | -- | -- | 0.00 | -- | -- | -- | 25.39 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Beam Therapeutics Inc's reporting currency: US Dollar USD
64.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Dec 2025 | 12.47m | 12.29% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 10.26m | 10.11% |
| Farallon Capital Management LLCas of 31 Dec 2025 | 10.06m | 9.92% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.38m | 8.26% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 6.99m | 6.89% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 5.23m | 5.15% |
| Amova Asset Management Americas, Inc.as of 31 Dec 2025 | 4.41m | 4.35% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 2.60m | 2.56% |
| Kynam Capital Management LPas of 31 Dec 2025 | 2.44m | 2.41% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.35m | 2.32% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
